Lantheus Holdings Option Alert: Mar 21 $75 Puts at the Bid: 1200 vs 3031 OI; Earnings 2/26 Before Open 

Lantheus Holdings Option Alert: Mar 21 $75 Puts at the Bid: 1200 @ $4.5 vs 3031 OI; Earnings 2/26 Before Open Ref=$79.66

Lantheus Holdings 株価情報 (NASDAQ: LNTH)

Lantheus Holdings (NASDAQ:LNTH) 株価情報

Lantheus Holdings

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

Lantheus Holdings Inc

On February 12, it was revealed in an SEC filing that Khanh Phuong Morrow, Board Member at Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) executed a significant exercise of company stock options.
What Happened: Morrow, Board Member at Lantheus Holdings, made a strategic move by exercising stock options for 0 shares of LNTH as detailed in a Form 4 filing on Wednesday with the <a href="https://www.sec.gov/Archives/edgar/data/0001521036/000106299325002208//Archives/edgar/data/1521036/000106299325002208/0001062993-25-002208-index.htm">U.S. Securities and Exchange Commission</a>. The transaction value amounted to $0.
Currently, Lantheus Holdings shares are trading up 0.95%, priced at $82.88 during Thursday's morning. This values Morrow's 0 shares at $0.
<h3>All You Need to Know About Lantheus Holdings</h3>
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
<h3>Lantheus Holdings's Economic Impact: An Analysis</h3>
Revenue Growth: Over the 3 months period, Lantheus Holdings showcased positive performance, achieving a revenue growth rate of 18.37% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Analyzing Profitability Metrics:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 63.93%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Lantheus Holdings's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 1.89.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.52, Lantheus Holdings adopts a prudent financial strategy, indicating a balanced approach to debt management.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 13.64 is lower than the industry average, implying a discounted valuation for Lantheus Holdings's stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 3.9 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio of 8.37 trails industry averages, indicating a potential disparity in market valuation that could be advantageous for investors.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Exploring the Significance of Insider Trading</h3>
It's important to note that insider transactions alone should not dictate investment decisions, but they can provide valuable insights.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Cracking Transaction Codes</h3>
When dissecting transactions, the focal point for <a href="https://www.benzinga.com/money/investing-tools">investors</a> is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001521036">Check Out The Full List Of Lantheus Holdings's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Insider Trades

Trading Ideas

LNTH

Insider Decision Unfolding At Lantheus Holdings: Khanh Phuong Morrow Exercises Options, Resulting In $0

Biotech

General

Lantheus Holdings Announces Piflufolastat F 18 Data Will Be Presented At The 2025 American Society Of Clinical Oncology Genitourinary Cancers Symposium, Taking Place February 13-15, 2025, In San Francisco, CA

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LXRX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$1.00</td>
<td>$168.9K</td>
<td>10.7K</td>
<td>17.1K</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$93.00</td>
<td>$49.9K</td>
<td>25</td>
<td>604</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$130.00</td>
<td>$42.9K</td>
<td>6.5K</td>
<td>520</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$57.50</td>
<td>$53.5K</td>
<td>1.9K</td>
<td>112</td>
</tr>
<tr>
<td>AKRO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$30.00</td>
<td>$102.8K</td>
<td>436</td>
<td>56</td>
</tr>
<tr>
<td>LNTH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$100.00</td>
<td>$45.0K</td>
<td>124</td>
<td>47</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$650.00</td>
<td>$60.4K</td>
<td>70</td>
<td>30</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$720.00</td>
<td>$65.7K</td>
<td>6</td>
<td>25</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$540.00</td>
<td>$27.6K</td>
<td>625</td>
<td>21</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding LXRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>), we observe a call option sweep with bearish sentiment. It expires in 24 day(s) on February 21, 2025. Parties traded 11262 contract(s) at a $1.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $168.9K, with a price of $15.0 per contract. There were 10734 open contracts at this strike prior to today, and today 17155 contract(s) were bought and sold. 
• For MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we notice a call option sweep that happens to be bearish, expiring in 24 day(s) on February 21, 2025. This event was a transfer of 316 contract(s) at a $93.00 strike. This particular call needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $49.9K, with a price of $158.0 per contract. There were 25 open contracts at this strike prior to today, and today 604 contract(s) were bought and sold. 
• Regarding ABT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), we observe a call option sweep with bearish sentiment. It expires in 24 day(s) on February 21, 2025. Parties traded 272 contract(s) at a $130.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $42.9K, with a price of $158.0 per contract. There were 6570 open contracts at this strike prior to today, and today 520 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a call option sweep with bullish sentiment. It expires in 143 day(s) on June 20, 2025. Parties traded 100 contract(s) at a $57.50 strike. This particular call needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $53.5K, with a price of $535.0 per contract. There were 1923 open contracts at this strike prior to today, and today 112 contract(s) were bought and sold. 
• Regarding AKRO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKRO#NASDAQ">AKRO</a>), we observe a call option trade with neutral sentiment. It expires in 24 day(s) on February 21, 2025. Parties traded 46 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $102.8K, with a price of $2235.0 per contract. There were 436 open contracts at this strike prior to today, and today 56 contract(s) were bought and sold. 
• For LNTH (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>), we notice a call option sweep that happens to be bullish, expiring in 143 day(s) on June 20, 2025. This event was a transfer of 47 contract(s) at a $100.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $45.0K, with a price of $968.0 per contract. There were 124 open contracts at this strike prior to today, and today 47 contract(s) were bought and sold. 
• Regarding TMO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), we observe a call option trade with bearish sentiment. It expires in 234 day(s) on September 19, 2025. Parties traded 30 contract(s) at a $650.00 strike. The total cost received by the writing party (or parties) was $60.4K, with a price of $2016.0 per contract. There were 70 open contracts at this strike prior to today, and today 30 contract(s) were bought and sold. 
• Regarding REGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>), we observe a call option trade with bullish sentiment. It expires in 52 day(s) on March 21, 2025. Parties traded 25 contract(s) at a $720.00 strike. The total cost received by the writing party (or parties) was $65.7K, with a price of $2630.0 per contract. There were 6 open contracts at this strike prior to today, and today 25 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a call option trade that happens to be bullish, expiring in 79 day(s) on April 17, 2025. This event was a transfer of 10 contract(s) at a $540.00 strike. The total cost received by the writing party (or parties) was $27.6K, with a price of $2760.0 per contract. There were 625 open contracts at this strike prior to today, and today 21 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AKRO

LXRX

REGN

9 Health Care Stocks With Whale Alerts In Today's Session

On Tuesday,&nbsp;Lantheus Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) agreed to acquire Evergreen Theragnostics, Inc. in an all-cash transaction involving an upfront payment of&nbsp;$250 million&nbsp;and up to an additional&nbsp;$752.5 million&nbsp;in <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n43261004/lantheus-to-acquire-evergreen-theragnostics-for-upfront-payment-of-250-million-to-drive-strategic-" rel="noreferrer noopener">potential milestone payments</a>.
Evergreen is a clinical-stage radiopharmaceutical company that offers Contract Development and Manufacturing (CDMO) services, drug discovery, and the commercialization of proprietary products.
This transaction will solidify Lantheus&#8217; capabilities as a fully integrated radiopharmaceutical company.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39717130/new-reimbursement-rules-for-diagnostic-radiopharmaceuticals-is-undoubtedly-positive" rel="noreferrer noopener">New Reimbursement Rules For Diagnostic Radiopharmaceuticals Is &#8216;Undoubtedly&#8217; Positive for Lantheus: Analyst</a>
The acquisition also expands Lantheus&#8217; oncology diagnostic pipeline by adding both OCTEVY, a registrational-stage PET diagnostic agent for certain neuroendocrine tumors (NETs) that could complement Lantheus&#8217; therapeutic candidate PNT2003, as well as several clinical and pre-clinical novel theranostic pairs.
The transaction is expected to close in the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n43261004/lantheus-to-acquire-evergreen-theragnostics-for-upfront-payment-of-250-million-to-drive-strategic-" rel="noreferrer noopener">second half of 2025</a>.
The company also reaffirmed its fiscal year 2024 revenue guidance of $1.51 billion—$1.52 billion and adjusted EPS of $6.65-$6.70, compared to consensus of $1.52 billion and <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">$6.74, respectively</a>.
Last week, Lantheus agreed to acquire Life Molecular Imaging in an all-cash transaction consisting of an upfront payment of $350 million and up to an additional $400 million in potential earn-out and milestone payments.
Life Molecular, a Life Healthcare Group Holdings Ltd&#8217;s subsidiary, offers Positron Emission Tomography (PET) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42937211/lantheus-to-acquire-life-molecular-imaging-for-an-upfront-payment-of-350-million-to-accelerate-inn" rel="noreferrer noopener">radiopharmaceutical diagnostics</a>.
The acquisition is expected to immediately enhance Lantheus&#8217; near and long-term growth profile and establish a commercial Alzheimer&#8217;s disease (AD) franchise with the addition of Neuraceq&nbsp;(florbetaben F18 injection), a F-18 radioactive diagnostic agent indicated for PET imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for AD and other causes of cognitive decline.
The transaction is expected to be accretive to Lantheus&#8217; Adjusted Earnings Per Share within 12 months of close.
Price Action: At last check on Tuesday, LNTH stock was down 5.56% to $92.85.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43260646/microsoft-eyes-tiktok-us-deal-as-trump-confirms-acquisition-talks-are-underway" target="_blank" rel="noreferrer noopener">Microsoft Eyes TikTok US Deal, Trump Says Acquisition Talks Are Underway</a></li>
</ul>

Health Care

Movers

Lantheus To Buy Evergreen Theragnostics For Over $1 Billion To Bolster Its Cancer Radiopharmaceutical Portfolio

WIIM

Lantheus shares are trading lower after the company issued FY24 adjusted EPS guidance below estimates. Additionally, the company announced it agreed to acquire Evergreen Theragnostics.

Earnings

Guidance

Lantheus Reaffirms FY 2024 Revenue Of $1.51B-$1.52B, And Adjusted EPS Of $6.65-$6.70 Compared To Consensus Of $1.52B And $6.74, Respectively

<ul>
<li>Advances radiopharmaceutical leadership with addition of scalable manufacturing infrastructure and end-to-end clinical development capabilities</li>
<li>Adds OCTEVY, a registrational-stage diagnostic asset, targeting neuroendocrine tumors that is complementary to Lantheus' therapeutic agent, PNT2003</li>
<li>Expands oncology radiopharmaceutical pipeline with multiple clinical and pre-clinical theranostic pairs</li>
</ul>

Lantheus Agreed To Acquire Evergreen Theragnostics In An All-cash Transaction Consisting Of An Upfront Payment Of $250M And Up To An Additional $752.5M In Potential Milestone Payments

President Joe Biden prioritized <a href="https://www.benzinga.com/markets/cannabis/25/01/43054504/biden-commutes-sentences-of-nearly-2500-convicted-of-non-violent-drug-offenses-no-mention-of-cannabis-prisoners">freeing non-violent drug offenders</a> during his final few days in the White House, but TikTok? That's President-elect Donald Trump's problem now. 
According to the <a href="https://apnews.com/article/tiktok-ban-trump-executive-order-1e95d9836bf6f8c0c245ed1c3234d968">Associated Press</a>, Biden has no intention of enforcing the ban, which takes effect on his last full day in office, Jan. 19, and one day <a href="https://www.benzinga.com/news/25/01/42995328/trump-inauguration-from-elon-musk-jeff-bezos-to-barack-obama-george-bush-and-bill-clinton-who-all-will-attend">before Trump&#8217;s inauguration</a>.
With a deadline looming, the app's fate lands in the hands of the so-called People's Bid for TikTok—backed by none other than Kevin O'Leary of &#8220;Shark Tank&#8221; and billionaire Frank McCourt. Apparently, TikTok's U.S. assets are still up for grabs, but no word yet on the price tag or whether a deal can realistically get done <a href="https://www.benzinga.com/general/social-media/25/01/43060894/supreme-court-upholds-tiktok-ban-ahead-of-trumps-inauguration">in a few days</a>.
<h2 class="wp-block-heading">Bankruptcy Block</h2>
Joann Inc. is stitching together a bankruptcy plan for the second time within 12 months. The Ohio-based fabric and crafts retailer is seeking a buyer for its portfolio of some 800 stores. 
Gordon Brothers Retail Partners emerged as the &#8220;stalking horse&#8221; bidder, but Joann remains hopeful for better offers—perhaps from someone who knows how to thread the needle.
Previously, the 82-year-old retailer was under the stewardship of private equity firm Leonard Green &amp; Partners, which acquired it via a $1.6 billion leveraged buyout in 2011. The firm buried the company under a pile of debt (<a href="https://wolfstreet.com/2024/03/18/brick-and-mortar-meltdown-fells-another-retailer-joann-inc-files-for-bankruptcy-3-years-after-ipo/">reportedly</a> $921 million in long-term debt as of Oct. 31, 2020) and <a href="https://www.benzinga.com/news/21/03/20048728/ipo-preview-roblox-coupang-joann-lead-busy-week-of-offerings">sent it public in 2021</a>. 
Joann went private again in <a href="https://apnews.com/article/joann-bankruptcy-chapter-11-filing-75093d4032907c59a45e472dd4e23229">March</a> 2024 while under Chapter 11 bankruptcy protection. The company managed to reduce its $1 billion total debt by about $500 million at the time.
Despite efforts to save itself last year, Joann is joining the growing quilt of recent retail casualties: Party City, Big Lots, LL Flooring, The Body Shop and The Container Store <a href="https://www.benzinga.com/news/legal/24/12/42710619/deal-dispatch-party-city-wraps-big-lots-goes-bust-container-store-continues">to name a few</a>.
Kirkland &amp; Ellis is handling legal matters, while Centerview Partners LLC offers financial advice. Alvarez &amp; Marsal North America, LLC is overseeing the restructuring process.
<h2 class="wp-block-heading">New On The Block</h2>
<ul>
<li>Investment firm KKR &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) hired Goldman Sachs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) to run an auction for its minority stake in Philippine fintech company Maya, Reuters reported. </li>
<li>New York-headquartered KKR owns more than 20% of Maya and the potential sale, if it goes through, could value Maya at more than $2 billion, one of the sources said.</li>
<li>DuPont de Nemours, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) is looking to <a href="https://www.benzinga.com/news/large-cap/25/01/43028181/chemical-company-dupont-electronics-business-separation-retains-water-business">jettison its electronics business</a>. The Wilmington, Delaware-based company expects the transaction to be completed by Nov. 1. DuPont also decided to retain its water business after evaluating strategic alternatives.</li>
<li>Ingevity Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVT#NYSE">NGVT</a>) is shopping its Performance Chemicals Industrial Specialties segment, which includes divesting parts of its North Charleston, South Carolina site. The company hopes to improve earnings cash flow and conclude the review process by year-end. Whether a transaction comes about <a href="https://www.benzinga.com/news/25/01/43027745/ingevity-explores-strategic-options-for-performance-chemicals-segment-to-strengthen-portfolio-projects-fy24-revenue-at-1-40-billion">remains to be seen</a>. </li>
<li>S&amp;W Seed Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANW#NASDAQ">SANW</a>) is up for sale. It&#8217;s also considering a merger or recapitalization as part of a larger strategic review. The Longmont, Colorado-based company has already sold its Australia subsidiary. &#8220;We continue to support all initiatives that optimize shareholder value and will consider the full range of potential strategic alternatives to ensure S&amp;W Seed is best positioned for future success,&#8221; chairman Alan Willits said.</li>
</ul>
See Also: <a href="https://www.benzinga.com/25/01/43046722/starship-explodes-during-flight-test-elon-musk-says-success-is-uncertain-but-entertainment-is-guaranteed">Starship Explodes During Flight Test, Elon Musk Says: &#8216;Success Is Uncertain, But Entertainment Is Guaranteed!&#8217;</a>
<h2 class="wp-block-heading">Updates From The Block</h2>
<ul>
<li>Lourenco Goncalves raised eyebrows during a Monday press conference. According to <a href="https://www.bloomberg.com/news/articles/2025-01-14/cliffs-ceo-rips-evil-japan-and-doubles-down-on-america-first">Bloomberg</a>, the CEO of Cleveland-Cliffs Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) called Japan, a U.S. ally, &#8220;evil&#8221; and accused it of teaching China harmful practices like dumping and overproduction. His comments came as Cleveland-Cliffs eyes a new bid for U.S. Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>), following Biden&#8217;s decision to block Nippon Steel&#8216;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NPSCY#OTC">NPSCY</a>) <a href="https://www.benzinga.com/trading-ideas/movers/25/01/42787508/biden-blocks-14-9b-us-steel-takeover-shares-plunge">$14 billion acquisition attempt</a>. While positioning his company as a potential buyer, Goncalves&#8217; rhetoric escalated tensions within the steel industry. Nippon is now looking to Trump to <a href="https://www.benzinga.com/news/25/01/42994950/nippon-steel-eyes-trump-administration-to-revive-15b-us-steel-deal-blocked-by-biden-well-do-whatever-it-takes">help close the deal</a>. </li>
<li>T-Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) will buy Vistar Media for $600 million. The telecom company expects the deal to strengthen its advertising business, Reuters reported. </li>
</ul>
Deals in the biotech and pharmaceutical sectors piled up this week. Here&#8217;s a sample of Benzinga&#8217;s coverage:
<ul>
<li>Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) submitted an unsolicited bid to acquire all of the outstanding shares of Sage Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) that it does not already own <a href="https://www.benzinga.com/25/01/42957657/biogens-push-for-sage-therapeutics-could-strengthen-its-neurology-strategy-analysts-say">for $7.22 per share</a>. Goldman Sachs analyst Salveen Richter believes the proposal makes strategic sense, considering the financial success of the Zurzuvae launch for postpartum depression (PPD).</li>
<li>GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) <a href="https://www.benzinga.com/25/01/42950025/gsk-to-buy-us-based-stomach-cancer-drug-developer-for-over-1-billion">agreed to acquire</a> IDRx, Inc., a biopharmaceutical company focused on precision therapeutics for gastrointestinal stromal tumors (GIST), for $1 billion. The deal may require an additional $150 million from GSK after certain regulatory approval milestones. </li>
<li>Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) scooped up Scorpion Therapeutics&#8217; early-stage <a href="https://www.benzinga.com/25/01/42949261/eli-lilly-scoops-up-scorpion-therapeutics-early-stage-cancer-program-for-25-billion">cancer program for $2.5 billion</a>. </li>
<li>Like Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) and AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) is seeking to bolster its neuropsychiatric portfolio<a href="https://www.benzinga.com/general/biotech/25/01/42948170/like-bristol-myers-squibb-and-abbvie-johnson-johnson-seeks-to-bolster-neuropsychiatric-portfolio-with-15-billion-deal"> with a $15 billion deal</a></li>
<li>Crown Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) offered to acquire all outstanding common shares of Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) at $3.10 per share.</li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) agreed to a deal with Decoy Therapeutics, a preclinical biotech focused on peptide conjugate therapeutics. The merged entity will target unmet needs in respiratory diseases and GI oncology.</li>
<li>Lantheus Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) strengthens its radiopharmaceutical position with<a href="https://www.benzinga.com/m-a/25/01/42937565/lantheus-strengthens-radiopharmaceutical-leadership-with-350m-acquisition-of-life-molecular-imaging"> $350 million acquisition of Life Molecular Imaging</a>.</li>
</ul>
For last week&#8217;s edition of Deal Dispatch, <a href="https://www.benzinga.com/ma/25/01/42921113/deal-dispatch-td-bank-charles-schwab-eyenovia-smart-share-hit-auction-block">click here</a>.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/real-estate/25/01/43055513/eccentric-billionaire-howard-hughes-former-miami-estate-on-market-for-55-5-million">Eccentric Billionaire, Legendary Filmmaker Howard Hughes&#8217; Former Miami Estate On Market For $55.5 Million</a></li>
</ul>
Image created with a photo from Shutterstock.

ABBV

BIIB

NGVT

NPSCY

RVNC

SAGE

SANW

SLRX

TMUS

Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt

Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Lantheus Holdings, revealing an average target of $121.75, a high estimate of $143.00, and a low estimate of $112.00. Observing a downward trend, the current average is 1.81% lower than the prior average price target of $124.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1736881258_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Lantheus Holdings among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$112.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Paul Choi</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$143.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$120.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$112.00</td>
<td>$125.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Lantheus Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Lantheus Holdings compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Lantheus Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Lantheus Holdings's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/LNTH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Lantheus Holdings analyst ratings.</a>
<h2>About Lantheus Holdings</h2>
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
<h3>Lantheus Holdings: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Over the 3 months period, Lantheus Holdings showcased positive performance, achieving a revenue growth rate of 18.37% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Lantheus Holdings's net margin is impressive, surpassing industry averages. With a net margin of 34.61%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Lantheus Holdings's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 11.88% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Lantheus Holdings's ROA stands out, surpassing industry averages. With an impressive ROA of 6.57%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.52.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

What 4 Analyst Ratings Have To Say About Lantheus Holdings

JMP Securities analyst David Turkaly reiterates Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) with a Market Outperform and maintains $112 price target.

Price Target

Reiteration

JMP Securities Reiterates Market Outperform on Lantheus Holdings, Maintains $112 Price Target

Lantheus Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) shares are trading lower by 4.4% to $91.64 during Monday&#8217;s session after the company announced a <a href="https://www.benzinga.com/pressreleases/25/01/g42937211/lantheus-to-acquire-life-molecular-imaging-for-an-upfront-payment-of-350-million-to-accelerate-inn">$350 million acquisition</a>.
What To Know: Lantheus Holdings announced the acquisition of Life Molecular Imaging Ltd. in a deal valued at up to $750 million, including $350 million upfront and up to $400 million in milestone payments. 
The company says the acquisition expands Lantheus' presence in Alzheimer's disease (AD) diagnostics with Neuraceq, an F-18 radioactive diagnostic agent for PET imaging of β-amyloid plaque in cognitively impaired patients.
Lantheus says Life Molecular brings advanced R&amp;D capabilities, international infrastructure and a strong commercial presence, enabling Lantheus to enhance its diagnostic and therapeutic offerings. 
CEO Brian Markison highlighted the acquisition&#8217;s alignment with Lantheus' growth strategy, emphasizing its potential to improve patient outcomes and deliver shareholder value.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42944934/wall-street-slashes-interest-rate-cut-bets-after-jobs-data-are-hikes-back-on-the-table">Wall Street Slashes Interest Rate Cut Bets After Jobs Data: Are Hikes Back On The Table?</a>
<h2 class="wp-block-heading">How To Buy LNTH Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Lantheus Holdings&#8217; case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, LNTH has a 52-week high of $126.89 and a 52-week low of $50.20.

Why Lantheus Holdings (LNTH) Stock Is Down 4%

Lantheus Holdings shares are trading lower after the company announced a $350 million acquisition.

<ul>
<li>Enhances Lantheus' growth profile with Neuraceq&#xAE;, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer's Disease</li>
<li>Advances Lantheus' radiopharmaceutical leadership with addition of Alzheimer's radiodiagnostic commercial infrastructure, expanded pipeline, and enhanced R&amp;D capabilities</li>
<li>Transaction expected to be accretive to adjusted EPS within the first 12 months</li>
<li>Company to host conference call on January 13, 2025, at 8:30 AM EST</li>
</ul>

Lantheus Strengthens Radiopharmaceutical Leadership With $350M Acquisition Of Life Molecular Imaging

<ul>
<li>Private placement to radiopharmaceutical industry leader Lantheus, for US$5.0 million</li>
<li>Placement at A$0.060 per share, representing a premium of 150% to the last closing price of A$0.024</li>
<li>Lantheus shareholding in Radiopharm increases to 12.16% following the placement</li>
<li>The funds raised will be applied to the development of Radiopharm's clinical pipeline</li>
</ul>
SYDNEY, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that it has executed a subscription agreement for a private placement of ordinary shares to Lantheus Holdings Inc. ( "Lantheus"), raising US$5.0 million (A$8.0 million).
The placement of 133 million shares was completed at an issue price of A$0.060 per share, representing a 150% premium to the last traded price of RAD shares (A$0.024). Settlement is expected to occur within 7 days.
The placement replaces 6-month options that the Company issued in August 2024 (see ASX announcement 20 June 2024).

Offerings

Contracts

RADX

Radiopharm Theranostics Executed A Subscription Agreement For A Private Placement Of Ordinary Shares To Lantheus Holdings Inc., Raising $5M

Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) has outperformed the market over the past 5 years by 23.29% on an annualized basis producing an average annual return of 36.08%. Currently, Lantheus Holdings has a market capitalization of $6.19 billion. 
Buying $1000 In LNTH: If an investor had bought $1000 of LNTH stock 5 years ago, it would be worth $4,630.01 today based on a price of $89.16 for LNTH at the time of writing.
<h3>Lantheus Holdings's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1735920908_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

A substantial insider activity was disclosed on December 24, as MARKISON, CEO at Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>), reported the exercise of a large sell of company stock options.
What Happened: MARKISON, CEO at Lantheus Holdings, made a strategic move by exercising stock options for 32,768 shares of LNTH as detailed in a Form 4 filing on Tuesday with the <a href="https://www.sec.gov/Archives/edgar/data/0001521036/000106299324021182//Archives/edgar/data/1521036/000106299324021182/0001062993-24-021182-index.htm">U.S. Securities and Exchange Commission</a>. The transaction value amounted to $2,731,057.
Lantheus Holdings shares are trading, exhibiting up of 1.64% and priced at $92.5 during Tuesday's morning. This values MARKISON's 32,768 shares at $2,731,057.
<h3>About Lantheus Holdings</h3>
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
<h3>Lantheus Holdings's Economic Impact: An Analysis</h3>
Positive Revenue Trend: Examining Lantheus Holdings's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 18.37% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 63.93%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Lantheus Holdings's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 1.89.
</li>
</ul>
Debt Management: Lantheus Holdings's debt-to-equity ratio is below the industry average. With a ratio of 0.52, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
In-Depth Valuation Examination:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 15.12 is lower than the industry average, implying a discounted valuation for Lantheus Holdings's stock.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 4.32 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Lantheus Holdings's EV/EBITDA ratio at 9.32 suggests potential undervaluation, falling below industry averages.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Breaking Down the Significance of Transaction Codes</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001521036">Check Out The Full List Of Lantheus Holdings's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options Exercise: BRIAN MARKISON At Lantheus Holdings Realizes $2.73M

In the current session, the stock is trading at $93.06, after a 0.44% spike. Over the past month, Lantheus Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) stock increased by 7.65%, and in the past year, by 56.81%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1734546613_0.png" alt="Past Year Chart" />

<h3>Lantheus Holdings P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Lantheus Holdings has a lower P/E than the aggregate P/E of 48.6 of the Health Care Equipment &amp; Supplies industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1734546613_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

P/E Ratio Insights for Lantheus Holdings

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Goldman Sachs analyst Paul Choi initiated coverage on Lantheus Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) with a Buy rating and announced a price target of $143. Lantheus shares closed at $92.66 on Tuesday. See how other analysts view this stock.</li>
<li>DA Davidson analyst Lucky Schreiner initiated coverage on Box, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) with a Buy rating and announced a price target of $45. Box shares closed at $32.07 on Tuesday. <a href="https://www.benzinga.com/quote/KR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Brookline Capital analyst Kumaraguru Raja initiated coverage on Quince Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNCX#NASDAQ">QNCX</a>) with a Buy rating and announced a price target of $9. Quince Therapeutics shares closed at $1.84 on Tuesday. <a href="https://www.benzinga.com/quote/KR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Tazeen Ahmad initiated coverage on KalVista Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALV#NASDAQ">KALV</a>) with a Buy rating and announced a price target of $22. KalVista Pharma shares closed at $8.65 on Tuesday. See how other analysts view this stock.</li>
<li>Raymond James analyst Andrew Marok initiated coverage on DoubleVerify Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DV#NYSE">DV</a>) with an Outperform rating and announced a price target of $25. Fluor shares closed at $19.95 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying BOX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="507" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18100141/image-159-1024x507.png" alt="" class="wp-image-697929" style="width:604px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18100141/image-159-1024x507.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18100141/image-159-300x148.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18100141/image-159-768x380.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18100141/image-159.png 1126w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42551008/top-3-health-care-stocks-that-may-explode-in-q4">Read This Next: </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42551008/top-3-health-care-stocks-that-may-explode-in-q4">Top 3 Health Care Stocks That May Explode In Q4</a></li>
</ul>

Initiation

KALV

QNCX

This Box Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Goldman Sachs analyst Paul Choi initiates coverage on Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) with a Buy rating and announces Price Target of $143.

Goldman Sachs Initiates Coverage On Lantheus Holdings with Buy Rating, Announces Price Target of $143

Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) has outperformed the market over the past 5 years by 20.97% on an annualized basis producing an average annual return of 34.66%. Currently, Lantheus Holdings has a market capitalization of $6.35 billion. 
Buying $1000 In LNTH: If an investor had bought $1000 of LNTH stock 5 years ago, it would be worth $4,461.65 today based on a price of $91.42 for LNTH at the time of writing.
<h3>Lantheus Holdings's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734102018_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Lantheus Holdings Stock In The Last 5 Years

Press Releases

Lantheus Continues to Commend CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals and Reaffirms Outlook for PYLARIFY's Blockbuster Status for 2025

Lantheus to Present at the Jefferies London Healthcare Conference

Lantheus Announces Share Repurchase Program

Lantheus to Acquire Life Molecular Imaging for an Upfront Payment of $350 Million to Accelerate Innovation for Patients in the Growing Alzheimer's Disease Radiodiagnostic Market

Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader

Comments

Lantheus Holdings

Unusual Options Activity for

ニュース

パートナーシップ

ベンジンガ・グローバル